Abstract
The description of the allosteric modification of receptors to affect changes in their function requires a model that considers the effects of the modulator on both agonist affinity and efficacy. A model is presented which describes changes in affinity in terms of the constant α (ratio of affinity in the presence vs the absence of modulator) and also the constant ξ (ratio of intrinsic efficacy of the agonist in the presence vs absence of modulator). This allows independent effects of both affinity and efficacy and allows the modeling of any change in the dose-response curve to an agonist after treatment with modulator. Examples are given where this type of model can predict effects of modulators that reduce efficacy but actually increase affinity of agonist (i.e. ifenprodil) and also of modulators that block the action of some agonists (the CXCR4 agonist SDF-1α by the antagonist AMD3100) but not others for the same receptor (SDF-1α peptide fragments RSVM and ASLW).
Keywords: allosteric effects, radioligand binding assay, NMDA receptor, HIV entry, CXCR4, Probe
Current Neuropharmacology
Title: Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs
Volume: 5 Issue: 3
Author(s): Terry Kenakin
Affiliation:
Keywords: allosteric effects, radioligand binding assay, NMDA receptor, HIV entry, CXCR4, Probe
Abstract: The description of the allosteric modification of receptors to affect changes in their function requires a model that considers the effects of the modulator on both agonist affinity and efficacy. A model is presented which describes changes in affinity in terms of the constant α (ratio of affinity in the presence vs the absence of modulator) and also the constant ξ (ratio of intrinsic efficacy of the agonist in the presence vs absence of modulator). This allows independent effects of both affinity and efficacy and allows the modeling of any change in the dose-response curve to an agonist after treatment with modulator. Examples are given where this type of model can predict effects of modulators that reduce efficacy but actually increase affinity of agonist (i.e. ifenprodil) and also of modulators that block the action of some agonists (the CXCR4 agonist SDF-1α by the antagonist AMD3100) but not others for the same receptor (SDF-1α peptide fragments RSVM and ASLW).
Export Options
About this article
Cite this article as:
Kenakin Terry, Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs, Current Neuropharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157015907781695973
DOI https://dx.doi.org/10.2174/157015907781695973 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia
CNS & Neurological Disorders - Drug Targets Stem Cells in Skeletal Tissue Engineering: Technologies and Models
Current Stem Cell Research & Therapy Synthesis and Characterization of a Nylon/Titanium as Hybrid Biomaterial
Recent Patents on Corrosion Science Renal Solute Transporters and Their Relevance to Serum Urate Disorder
Current Hypertension Reviews Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions
Drug Metabolism Letters Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design Editorial [ Hot Topic:Magic Bullets and Arrows: Biologic Approaches to Treat Substance Use Disorders (Guest Editor: Phil Skolnick and Nora D. Volkow)]
CNS & Neurological Disorders - Drug Targets Synthesis and Structure-Activity Relationship Studies of <i>N</i>-monosubstituted Aroylthioureas as Urease Inhibitors
Medicinal Chemistry Quantum Chemical Assessment of the Interaction of Potential Anticorrosion Additives with Steel Surface
Innovations in Corrosion and Materials Science (Discontinued) Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Meet the Editorial Board:
Current Alzheimer Research Asymmetric Dimethyl-L-Arginine (ADMA): A Possible Link Between Homocyst(e)ine and Endothelial Dysfunction
Current Drug Metabolism Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research The Green Light on Ketamine: Considerations for On-Road Safety
Current Drug Abuse Reviews The First Case Report of Kabuki Syndrome from the National Iranian Registry of Primary Immunodeficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Serotonin and Cognitive Flexibility: Neuroimaging Studies into the Effect of Acute Tryptophan Depletion in Healthy Volunteers
Current Medicinal Chemistry Glucocorticoid Receptor Antagonists
Current Topics in Medicinal Chemistry Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science